Floatz logo

zx008

Dravet Syndrome

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.UNKNOWNPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Dravet Syndrome cohort.

Asset / SponsorPhaseRating
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)-
The University of Texas Health Science Center, Houston
Phase 4BBB
Rna, (P-Thio)[2?-O-(2-Methoxyethyl)](A-G-M?U-M?U-G-G-A-G-M?C-A-A-G-A-M?U-M?U-A-M?U-M?C)
Stoke Therapeutics, Inc
Phase 3BB
Bexicaserin
Longboard Pharmaceuticals
Phase 3BB
gwp42003-p
Jazz Pharmaceuticals
Phase 3BB
Clemizole
Epygenix
Phase 3BB

View all 15 →

Same molecule, other indications

zx008 is also rated in:

Lennox-Gastaut syndromeDormant
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →